the bpc-157 reference.

BPC-157 (also written BPC 157, BPC157, or Body Protection Compound 157) is a synthetic pentadecapeptide consisting of 15 amino acids (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It was originally derived from a larger gastric protective protein fragment isolated from human gastric juice by Sikiric and colleagues in 1993.

BPC-157 is not a ballpoint pen, writing implement, or office supply. It is a research peptide compound. The term BPC-157 peptide pen refers to a pre-filled peptide delivery device used in laboratory research settings, not a writing instrument.

The full chemical name is body protection compound 157, with the historical clinical-trial designation PL14736 from early Pliva-sponsored work on inflammatory bowel disease. The peptide has a molecular mass of approximately 1419.5 Da and is unusually stable in acidic environments, which is part of why the original Zagreb group characterised it as a candidate gastric cytoprotectant.

BPC-157 has no marketing authorisation as a pharmaceutical in any jurisdiction. The historical PL14736 designation reflects early-phase clinical trial work on inflammatory bowel disease that did not progress to approval. It is supplied as a research peptide for laboratory use only.

How BPC-157 differs from TB-500

BPC-157 and TB-500 are both research peptides studied for tissue-repair applications, but they are structurally and mechanistically distinct. BPC-157 is a pentadecapeptide (15 residues) derived from a human gastric protein fragment. TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid peptide. The two are frequently studied in combination; see the BPC-157 and TB-500 combination reference at /uae/guides/bpc-157-tb-500-uae.

Why BPC-157 is written as BPC-157, BPC 157, or PL14736

Four variant spellings appear across the literature and commercial sources. Each refers to the same compound.

The biological activity of BPC-157 in preclinical research is described across four principal mechanistic threads. None of these have been characterised in human clinical trials beyond early-phase work, and the dominant evidence base is rodent models.

Tendon and ligament research findings

Krivic and colleagues (J Orthop Res, 2006;24(5):982-989) examined BPC-157 in a rat Achilles tendon-to-bone detachment model. The published findings reported promoted tendon-to-bone healing in BPC-157-treated rats and a counter-effect against corticosteroid-induced aggravation of healing impairment.

Cerovecki and colleagues (J Orthop Res, 2010;28(9):1155-1161) extended the model to medial collateral ligament transection in rats. The published findings reported improved biomechanical properties of healing ligament tissue in BPC-157-treated subjects compared with controls.

Cellular mechanism in tendon fibroblasts

Chang and colleagues (J Appl Physiol, 2011;110(3):774-780) characterised BPC-157 effects on tendon fibroblast cultures. The published findings reported dose-dependent increases in cell migration, dose-dependent increases in survival under hydrogen peroxide stress, and corresponding increases in FAK and paxillin phosphorylation. The work provides a candidate cellular mechanism for the macroscopic tendon healing findings.

GI tract and inflammatory bowel disease research

Klicek and colleagues (J Pharmacol Sci, 2008;108(1):7-17) characterised BPC-157 effects in a rat colocutaneous fistula model. The published findings reported accelerated fistula closure and direct dependence on the nitric oxide system, demonstrated by L-NAME (an NO synthase inhibitor) and L-arginine co-treatment. The compound was tested in this work under the PL14736 clinical-trial designation.

All effects described in this section have been observed in preclinical research models, predominantly rodent. None constitute therapeutic claims or clinical findings.

References

The four primary peer-reviewed sources referenced in this guide. Researchers should consult the originals for full methods and context.

• Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. doi:10.1002/jor.20096.
• Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci. 2008;108(1):7-17. doi:10.1254/jphs.FP0072161.
• Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. doi:10.1002/jor.21107.
• Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010.

BPC-157 appears across four principal research application areas in the published literature. The dominant evidence base is rodent and in vitro studies; no large-scale human clinical trial data has been published outside the early-phase PL14736 work.

Musculoskeletal tissue repair research

The most heavily published preclinical application area outside the GI tract. Investigators study BPC-157 in tendon, ligament, muscle, and tendon-to-bone insertion injury models. The compound serves as a research benchmark for probing tissue-repair pathways across rodent acute injury designs.

Gastrointestinal research

The original research area and the basis for the compound's Body Protection Compound name. BPC-157 has been examined in gastric mucosal protection models, intestinal anastomosis healing, fistula closure (the PL14736 work), and inflammatory bowel disease models. Sikiric and colleagues at the University of Zagreb have driven the bulk of the published GI work.

Vascular and angiogenesis research

Preclinical models report effects on vascular endothelial growth factor signalling and microvessel formation. The angiogenic response is the candidate mechanism most often invoked to explain the cross-tissue repair effects observed across the BPC-157 literature.

Central nervous system research

Rodent studies have examined BPC-157 interaction with the dopaminergic and serotonergic systems in models of CNS injury and neurotransmitter pathway perturbation. This research area is less extensively documented than the GI and musculoskeletal work and remains preclinical.

A research peptide pen is a pre-filled delivery device pre-loaded with reconstituted peptide at a fixed concentration. The format originated in clinical injection devices and has been adapted for research handler use where dose consistency across experiments matters more than per-experiment flexibility.

The pen format differs from the lyophilised vial format in three practical ways. Pens arrive ready to use with no reconstitution step. The seal limits airborne contamination during repeated draws. The graduated dose mechanism provides volume consistency that is difficult to match with a manual draw from a stoppered vial.

The trade-off is rigidity. A pen format locks in the concentration set at manufacture, so researchers who need to vary working dilutions across a study still need to dilute the drawn aliquot into their experimental buffer. For a single-concentration study or a series of replicates at the same dose, the format reduces handler variance considerably.

The BodyPharm UAE BPC-157 product is supplied as a BPC-157 and TB-500 combination pen, the combination most frequently studied in tissue-repair research designs. See the combination reference for the rationale.

Research-grade BPC-157 is defined by the documentation that accompanies it. A peptide with a published synthesis route but no batch-specific Certificate of Analysis is not a research material; it is an unknown. Researchers procuring BPC-157 in the UAE or anywhere else should expect the following at minimum.

• HPLC purity greater than 98 percent, ideally above 99 percent for sensitive research applications.
• Mass spectrometry confirmation of the BPC-157 pentadecapeptide sequence and molecular mass (1419.5 Da).
• Batch-specific Certificate of Analysis from an independent third-party lab, not just an in-house result.
• Endotoxin testing where the material is intended for cell culture or animal research.
• Documented cold-chain handling from synthesis through shipping, with temperature logs available on request.

For the BodyPharm UAE BPC-157 and TB-500 combination pen, the per-batch lab report is published at /uae/lab-results/bpc-157-tb-500-pen. The CoA documents HPLC purity, mass spectrometry confirmation of both peptide sequences, and the in-house concentration assay. Independent third-party reports are available on request.

If there is no CoA, there is no peptide. Only powder.

Research peptides are not pharmaceuticals under UAE Federal Decree-Law No. 38 of 2024 and are not regulated as medicines. BPC-157 in the research peptide format is supplied for laboratory research use only, not for human or veterinary therapeutic use. Researchers are responsible for ensuring their handling and use comply with their institution's research governance and any applicable local research-ethics requirements.

The UAE has emerged as a regional hub for research peptide supply, partly because of the climate-driven cold-chain expertise developed across the GCC pharmaceutical distribution network. Suppliers operating from Dubai, Abu Dhabi, and Sharjah can typically meet same-day delivery to Dubai locations and one to three day delivery to other emirates.

Cold-chain shipping in the GCC requires considered packaging. Ambient temperatures across the summer months routinely exceed 40 degrees Celsius, well above the stability window for reconstituted peptide solutions. See the dedicated reference at peptide delivery and GCC cold chain for the operational considerations.

For the full UAE regulatory context covering research peptide procurement, including the relevant law citations and the distinction between research and therapeutic use, see Is it legal to buy peptides in Dubai and the UAE.

The questions below cover the most common queries from UAE-based researchers and procurement teams. Each answer is independently sourced and can be cross-referenced against the linked product pages and lab results.

BPC-157 sits within a broader research peptide category that BodyPharm UAE supplies and documents in parallel. The references below provide background on adjacent research compounds frequently studied alongside BPC-157.

For the full BodyPharm UAE research peptide catalogue with current batch CoAs, see /uae/peptides.